BioSpace News Archive

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today provides an update on plans for the further development of its lead compound fezagepras

Catamaran Bio, Inc., today announced an expansion and extension of its research collaboration with Branden Moriarity, PhD, of the University of Minnesota, to further advance the versatility of transposon engineering for arming CAR-NK cell therapies with functional attributes not found in earlier generations of cell therapies.

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a task order contract, with a ceiling value of $1.9 million, by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop well-characterized challenge material for therapeutic development.

Lineage Cell Therapeutics, Inc. today announced that full results from a Phase 1/2a clinical study of RG6501 will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022), to be held May 1 – 4, 2022 at the Colorado Convention Center in Denver, CO.

Avinger, Inc. today announced that the Company will effect a 1-for-20 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern time on Monday, March 14, 2022.

MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography technology, the TRIUX™ neo, by the University of Nebraska Medical Center.

Biotage has two financial goals in its business, an organic sales growth goal of 8 percent and a profitability goal of 15 percent.

Helixmith announced that their publication, “Gene therapy for diabetic neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor,” was one of the top-10 most-downloaded articles in Clinical and Translational Science in 2021.

Applied DNA Sciences, Inc. today announced that the two companies have executed a non-binding letter of intent (“LOI”) that outlines the terms of a collaborative research agreement (the “Definitive Agreement”) to investigate the feasibility of utilizing the Company’s LinearDNATM platform.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3 clinical trial investigating the use of Tempol for the treatment of COVID-19, met to evaluate the clinical and safety data from the first planned interim analysis.